The overall goal of treatment in spondyloarthritis (psoriatic arthritis [PsA] and axial spondyloarthitis [axSPA]) is to optimize patient quality of life by reducing symptoms, inflammation and structural damage. In this live symposium, expert faculty will discuss key clinical data for current and emerging therapeutic options for the management of patients with PsA and axSpA and highlight key factors that influence treatment selection for individual patients. Developed and offered by Medscape, LLC supported by UCB Biopharma SRL.
CME
